Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Iovance Biotherapeutics (IOVA) Net Margin (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Net Margin for 4 consecutive years, with 82.83% as the latest value for Q4 2025.

  • On a quarterly basis, Net Margin rose 2379.0% to 82.83% in Q4 2025 year-over-year; TTM through Dec 2025 was 148.37%, a 7847.0% increase, with the full-year FY2025 number at 148.37%, up 7847.0% from a year prior.
  • Net Margin was 82.83% for Q4 2025 at Iovance Biotherapeutics, up from 135.29% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 82.83% in Q4 2025 to a low of 44759.66% in Q2 2023.
  • A 3-year average of 10014.51% and a median of 235.59% in 2025 define the central range for Net Margin.
  • Peak YoY movement for Net Margin: skyrocketed 4444764bps in 2024, then soared 742bps in 2025.
  • Iovance Biotherapeutics' Net Margin stood at 24140.87% in 2023, then surged by 100bps to 106.62% in 2024, then grew by 22bps to 82.83% in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Net Margin are 82.83% (Q4 2025), 135.29% (Q3 2025), and 186.18% (Q2 2025).